Real-world treatment outcomes of peripheral T-cell lymphoma in the era of molecular targeted therapy.
Peripheral T-cell lymphomas show only modest improvements despite targeted therapies, highlighting an unmet need for better treatment approaches.
Real-world PTCL outcomes in the targeted therapy era show modest overall improvement but continued poor prognosis across subtypes, emphasizing the ongoing high unmet need. Subtype-specific analyses identify patients most likely to benefit from molecular targeted agents.
What the study was
- Study design
- Real-world retrospective cohort
- Population
- Peripheral T-cell lymphoma (PTCL) patients; real-world Japanese multicenter cohort
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Journal of clinical and experimental hematopathology
Why it surfaced
PTCL is a rare high-unmet-need malignancy; real-world outcomes in targeted therapy era informs clinical practice; publication year 2026 (vol 66) vs CRDT 2026-06-28.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.